# Cancer Cause and Prevention Research (93.393)

Source: https://welltoldgrants.com/programs/93-393-cancer-cause-and-prevention-research/  
Publisher: Well Told Grants. Data: USAspending.gov and Grants.gov, updated October 31, 2026.

Cancer Cause and Prevention Research is run by Department of Health and Human Services. From fiscal 2021 to 2025 it awarded $3.6 billion in 2,517 grants, about $1.4 million per award.

## Objectives

To identify cancer risks and risk reduction strategies, to identify factors that cause cancer in humans, and to discover and develop mechanisms for cancer prevention and preventive interventions in humans. Research programs include: (1) chemical, physical and molecular carcinogenesis; (2) screening, early detection and risk assessment, including biomarker discovery, development and validation; (3) epidemiology; (4) nutrition and bioactive food components; (5) immunology and vaccines; (6) field studies and statistics; (7) cancer chemoprevention and interception; (8) pre-clinical and clinical agent development; (9) organ site studies and clinical trials; (10) health-related quality of life and patient-centered outcomes; and (11) supportive care and management of symptoms and toxicities. Small Business Innovation Research (SBIR) program: To expand and improve the SBIR program; to stimulate technical innovation; to increase private sector commercialization of innovations derived from Federal research and development funding; to increase small business participation in Federal research and development; and to foster and encourage participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons.
Small Business Technology Transfer (STTR) program: To stimulate and foster scientific and technological innovation through cooperative research and development carried out between small business concerns and research institutions; to foster technology transfer through cooperative research and development between small business concerns and research institutions; to increase private sector commercialization of innovations derived from Federal research and development funding, and foster participation in innovation and entrepreneurship by women and socially/economically disadvantaged persons.

## Funding by fiscal year

| Year | Amount | Awards |
|---|---|---|
| 2021 | $647 million | 1,223 |
| 2022 | $703 million | 1,340 |
| 2023 | $723 million | 1,366 |
| 2024 | $731 million | 1,376 |
| 2025 | $803 million | 1,289 |

## Largest recipients

| Recipient | State | Amount |
|---|---|---|
| The Univeristy of Texas M.D. Anderson Cancer Center | Texas | $107 million |
| Sloan-Kettering Institute for Cancer Research | New York | $99.1 million |
| The Trustees of Columbia University in the City of New York | New York | $85.3 million |
| Dana-Farber Cancer Institute, Inc. | Massachusetts | $83.1 million |
| University of North Carolina at Chapel Hill | North Carolina | $76.1 million |
| Fred Hutchinson Cancer Center | Washington | $75.6 million |
| Vanderbilt University Medical Center | Tennessee | $74.0 million |
| Kaiser Foundation Hospitals | California | $66.2 million |
| The Regents of the University of California, San Francisco | California | $64.1 million |
| Mayo Clinic | Minnesota | $63.9 million |
| Regents of the University of Minnesota | Minnesota | $60.9 million |
| Baylor College of Medicine | Texas | $60.3 million |
| The Ohio State University | Ohio | $59.6 million |
| The Trustees of the University of Pennsylvania | Pennsylvania | $57.2 million |
| The General Hospital Corporation | Massachusetts | $57.1 million |
| University of Utah | Utah | $57.0 million |
| St Jude Children's Research Hospital Inc | Tennessee | $56.2 million |
| Regents of the University of Michigan | Michigan | $55.9 million |
| The Washington University | Missouri | $55.3 million |
| University of Southern California | California | $53.2 million |

## Open opportunities

- [Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-095-secondary-analysis-and-integration-of-existing-data-to/), closes November 6, 2026
- [Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)](https://welltoldgrants.com/grants/par-25-096-secondary-analysis-and-integration-of-existing-data-to/), closes November 17, 2026
- [Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)](https://welltoldgrants.com/grants/par-24-214-academic-research-enhancement-award-area-for-undergraduate/), closes January 7, 2027
- [Cancer Prevention and Control Clinical Trials Grant Program (R01 Clinical Trial Required)](https://welltoldgrants.com/grants/par-25-167-cancer-prevention-and-control-clinical-trials-grant-program/), closes January 7, 2027
- [National Cancer Institute's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (R01 Clinical Trial Required)](https://welltoldgrants.com/grants/par-25-081-national-cancer-institute-s-investigator-initiated-early/), closes January 7, 2027
- [Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-069-mechanisms-that-impact-cancer-risk-with-use-of/), closes January 7, 2027
- [Mechanisms that Impact Cancer Risk with Use of Incretin Mimetics (R21 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-070-mechanisms-that-impact-cancer-risk-with-use-of/), closes January 7, 2027
- [HEAL Initiative: Studies to Enable Analgesic Discovery (R61/R33 - Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/rfa-ns-25-023-heal-initiative-studies-to-enable-analgesic-discovery-r61/), closes January 15, 2027
- [Carcinogen Hazard Assessment Monographs Program (CHAMP) (R01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/rfa-ca-28-013-carcinogen-hazard-assessment-monographs-program-champ-r01/), closes February 9, 2027
- [NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-27-100-nih-cdc-and-fda-small-business-innovation-research/), closes April 5, 2027
- [NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-27-102-nih-small-business-technology-transfer-grant-parent-sttr/), closes April 5, 2027
- [Pancreatic Cancer Detection Consortium: Management and Data Coordination Unit (U24 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-28-057-pancreatic-cancer-detection-consortium-management-and-data/), closes May 25, 2027
- [Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-211-enhancing-mechanistic-research-on-precision-probiotic/), closes June 2, 2027
- [Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-210-enhancing-mechanistic-research-on-precision-probiotic/), closes June 2, 2027
- [Change of Recipient Organization (Type 7 Parent Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-24-254-change-of-recipient-organization-type-7-parent-clinical/), closes July 12, 2027
- [Successor-in-Interest (Type 6 Parent Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-24-253-successor-in-interest-type-6-parent-clinical-trial/), closes July 17, 2027
- [NIH Support for Conferences and Scientific Meetings (Parent R13 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/pa-25-080-nih-support-for-conferences-and-scientific-meetings-parent/), closes September 7, 2027
- [Integrating Biospecimen Science Approaches into Clinical Assay Development (U01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-325-integrating-biospecimen-science-approaches-into-clinical/), closes September 10, 2027
- [Utilizing the PLCO Biospecimens Resource to Bridge Gaps in Cancer Etiology and Early Detection Research (U01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-248-utilizing-the-plco-biospecimens-resource-to-bridge-gaps/), closes October 8, 2027
- [Early-Stage Development of Informatics Technologies for Cancer Research and Management (U01 Clinical Trial Optional)](https://welltoldgrants.com/grants/rfa-ca-27-019-early-stage-development-of-informatics-technologies-for/), closes October 19, 2027
- [Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Required)](https://welltoldgrants.com/grants/par-27-078-research-enhancement-award-program-reap-for-health/), closes October 25, 2027
- [Basic Research in Cancer Health Disparities (R21 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-244-basic-research-in-cancer-health-disparities-r21-clinical/), closes November 16, 2027
- [Advancing Healthcare for Older Adults from Populations that Experience Health Disparities (R01 - Clinical Trial Optional)](https://welltoldgrants.com/grants/par-24-273-advancing-healthcare-for-older-adults-from-populations-that/), closes January 7, 2028
- [Mechanisms that Impact Cancer Risk after Bariatric Surgery (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-043-mechanisms-that-impact-cancer-risk-after-bariatric-surgery/), closes January 7, 2028
- [Mechanisms that Impact Cancer Risk after Bariatric Surgery (R21 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-044-mechanisms-that-impact-cancer-risk-after-bariatric-surgery/), closes January 7, 2028
- [Integration of Imaging and Fluid-Based Tumor Monitoring in Cancer Therapy (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-175-integration-of-imaging-and-fluid-based-tumor-monitoring/), closes January 7, 2028
- [Clinical Characterization of Cancer Therapy-induced Adverse Sequelae and Mechanism-based Interventional Strategies (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-145-clinical-characterization-of-cancer-therapy-induced-adverse/), closes January 7, 2028
- [Modular R01s in Cancer Control and Population Sciences (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-25-172-modular-r01s-in-cancer-control-and-population-sciences/), closes January 7, 2028
- [Basic Research in Cancer Health Disparities (R01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-243-basic-research-in-cancer-health-disparities-r01-clinical/), closes January 7, 2028
- [Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Required)](https://welltoldgrants.com/grants/par-25-148-academic-research-enhancement-award-area-for-undergraduate/), closes January 7, 2028
- [The Role of Work in Health Disparities in the U.S. (R01 Clinical Trials Optional)](https://welltoldgrants.com/grants/par-25-292-the-role-of-work-in-health-disparities-in/), closes January 7, 2028
- [Academic Research Enhancement Award (AREA) for Undergraduate-Focused Institutions (R15 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-134-academic-research-enhancement-award-area-for-undergraduate/), closes January 7, 2028
- [Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-298-research-enhancement-award-program-reap-for-health/), closes January 7, 2028
- [Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-321-exploratory-developmental-bioengineering-research-grants/), closes January 7, 2028
- [Exploratory/Developmental Bioengineering Research Grants (EBRG) (R21 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-346-exploratory-developmental-bioengineering-research-grants/), closes January 7, 2028
- [NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/pa-25-304-nih-exploratory-developmental-research-project-grant-parent/), closes January 7, 2028
- [NIH Exploratory/Developmental Research Project Grant (Parent R21 Clinical Trial Required)](https://welltoldgrants.com/grants/pa-25-306-nih-exploratory-developmental-research-project-grant-parent/), closes January 7, 2028
- [NIH Research Project Grant (Parent R01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/pa-25-301-nih-research-project-grant-parent-r01-clinical-trial/), closes January 7, 2028
- [Stephen I. Katz Early Stage Investigator Research Project Grant (R01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-25-322-stephen-i-katz-early-stage-investigator-research-project/), closes August 25, 2028
- [Exploratory Grants in Cancer Control (R21 Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-25-253-exploratory-grants-in-cancer-control-r21-clinical-trial/), closes September 7, 2028
- [Method to Extend Research in Time (MERIT) Award Extension Request (Type 4 eSubmission Clinical Trial Optional)](https://welltoldgrants.com/grants/par-25-324-method-to-extend-research-in-time-merit-award/), closes September 7, 2028
- [Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-26-001-administrative-supplements-to-existing-nih-grants-and/), closes November 30, 2028
- [SBIR/STTR Commercialization Readiness Pilot (CRP) Program (Parent SB1 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-27-098-sbir-sttr-commercialization-readiness-pilot-crp-program/), closes April 5, 2029
- [NIH Small Business Innovation Research (SBIR) Phase IIB Strategic Breakthrough Award (Parent [R44] Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-27-101-nih-small-business-innovation-research-sbir-phase-iib/), closes April 5, 2029
- [NIH Collaborative International Research Project (Parent PF5 Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-26-002-nih-collaborative-international-research-project-parent-pf5/), closes May 7, 2029
- [Centers for AIDS Research (CFAR) and Developmental Centers for AIDS Research (D-CFAR) (P30 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-28-090-centers-for-aids-research-cfar-and-developmental-centers/), closes May 25, 2029
- [NIH Research Program Projects (Parent P01 Clinical Trial Optional)](https://welltoldgrants.com/grants/pa-27-061-nih-research-program-projects-parent-p01-clinical-trial/), closes May 25, 2029
- [Implementation Science to Advance HIV Prevention, Treatment, and Care (R61/R33 Clinical Trial Optional)](https://welltoldgrants.com/grants/rfa-ai-27-018-implementation-science-to-advance-hiv-prevention-treatment/), closes June 20, 2029
- [Research Opportunities in Cancer Epidemiology Cohort Studies (U01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-27-073-research-opportunities-in-cancer-epidemiology-cohort/), closes July 5, 2029
- [Bioengineering Research Grants (BRG) (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-27-072-bioengineering-research-grants-brg-r01-clinical-trial/), closes July 5, 2029
- [Early-Onset Cancers: Investigating Etiology, Mechanisms, and Early Detection Strategies (RP1 Clinical Trials Optional)](https://welltoldgrants.com/grants/par-28-014-early-onset-cancers-investigating-etiology-mechanisms-and/), closes October 11, 2029
- [Palliative Care Research Across the Lifespan: Leveraging the Palliative Care Consortium (R01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-27-090-palliative-care-research-across-the-lifespan-leveraging-the/), closes November 5, 2029
- [Pancreatic Cancer Detection Consortium: Research Units (U01 Clinical Trial Optional)](https://welltoldgrants.com/grants/par-28-056-pancreatic-cancer-detection-consortium-research-units-u01/), closes November 5, 2029
- [NCI Research Specialist (Clinician Scientist) Award (R50 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-27-089-nci-research-specialist-clinician-scientist-award-r50/), closes not stated
- [NCI Research Specialist Award for Core and Laboratory-based Scientists (R50 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-27-088-nci-research-specialist-award-for-core-and-laboratory/), closes not stated
- [Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/rfa-ca-26-010-canine-cancer-immunotherapy-network-k9cin-u01-clinical-trial/), closes not stated
- [Single Source: Coordinating Center (CC) for the Small Cell Lung Cancer (SCLC) Consortium (U24 Clinical Trial Not Allowed)](https://welltoldgrants.com/grants/par-27-009-single-source-coordinating-center-cc-for-the-small/), closes not stated
- [Implementation and Evaluation of Databases to Examine AIDS](https://welltoldgrants.com/grants/rfa-ai-28-025-implementation-and-evaluation-of-databases-to-examine-aids/), closes not stated
- [Advanced Development and Sustainment of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)](https://welltoldgrants.com/grants/rfa-ca-28-003-advanced-development-and-sustainment-of-informatics/), closes not stated
- [Investigator-Focused Award (Parent R35)](https://welltoldgrants.com/grants/par-28-037-investigator-focused-award-parent-r35/), closes not stated